TY - JOUR
T1 - New therapeutic approaches for equine protozoal myeloencephalitis
T2 - Pharmacokinetics of diclazuril sodium salts in horses
AU - Dirikolu, Levent
AU - Karpiesiuk, Wojciech
AU - Lehner, Andreas F.
AU - Hughes, Charlie
AU - Woods, William E.
AU - Harkins, John D.
AU - Boyles, Jeff
AU - Atkinson, Alfonza
AU - Granstrom, David E.
AU - Tobin, Thomas
PY - 2006/3
Y1 - 2006/3
N2 - Diclazuril, a triazine-based antiprotozoal agent, may have clinical application in the treatment of equine protozoal myeloencephalitis (EPM). Diclazuril was rapidly absorbed, with peak plasma concentrations occurring at 8 to 24 hours after oral-mucosal administration of diclazuril sodium salt. The mean oral bioavailability of diclazuril as Clinacox was 9.5% relative to oral-mucosal administration of diclazuril sodium salt; diclazuril in dimethyl sulfoxide administered orally was 50% less bioavailable than with oral-mucosal administration of diclazuril sodium salt. Diclazuril sodium salt has the potential to be used as a feed additive for the treatment and prophylaxis of EPM and various other apicomplexan-mediated diseases.
AB - Diclazuril, a triazine-based antiprotozoal agent, may have clinical application in the treatment of equine protozoal myeloencephalitis (EPM). Diclazuril was rapidly absorbed, with peak plasma concentrations occurring at 8 to 24 hours after oral-mucosal administration of diclazuril sodium salt. The mean oral bioavailability of diclazuril as Clinacox was 9.5% relative to oral-mucosal administration of diclazuril sodium salt; diclazuril in dimethyl sulfoxide administered orally was 50% less bioavailable than with oral-mucosal administration of diclazuril sodium salt. Diclazuril sodium salt has the potential to be used as a feed additive for the treatment and prophylaxis of EPM and various other apicomplexan-mediated diseases.
UR - http://www.scopus.com/inward/record.url?scp=33645941800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645941800&partnerID=8YFLogxK
M3 - Article
C2 - 16598684
AN - SCOPUS:33645941800
SN - 1528-3593
VL - 7
SP - 52-63+72
JO - Veterinary Therapeutics
JF - Veterinary Therapeutics
IS - 1
ER -